Expanded Access to ABBV-CLS-484
- Sponsor
- Calico Life Sciences LLC
- Study ID
- NCT06188975
- Status
- Available
Conditions
- Advanced Solid Tumor Cancer
Eligibility Criteria
- Sex
- All
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- DRUG: ABBV-CLS-484 — DRUG
Study Details
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-CLS-484 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Key Dates
- Status verified
- Dec 2023
Central Contacts
- ABBVIE CALL CENTER847.283.8955
Related Studies
- X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and MelanomaPHASE1 · Recruiting · Immunolight, LLC · Washington D.C., District of Columbia
- Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic TumorsPHASE1 · Recruiting · Calico Life Sciences LLC · Tucson, Arizona
- The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced CancerRecruiting · University of Colorado, Boulder · Aurora, Colorado